{
    "clinical_study": {
        "@rank": "160031", 
        "brief_summary": {
            "textblock": "This study will assess the safety and efficacy of Neotrofin in treating the peripheral\n      neuropathy that results from chemotherapy for cancer."
        }, 
        "brief_title": "Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy", 
        "condition": [
            "Peripheral Nervous System Diseases", 
            "Chemotherapy-Induced Peripheral Neuropathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Nervous System Diseases", 
                "Peripheral Nervous System Diseases", 
                "Demyelinating Diseases", 
                "Polyneuropathies", 
                "Nerve Compression Syndromes", 
                "Neurologic Manifestations", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Patient must have diagnosis of cancer and be receiving or have received chemotherapy\n             that has resulted in sensory or motor neuropathy.\n\n          -  Sensory or motor neuropathy must be >/= grade 2 per Common Toxicity Criteria at\n             baseline.\n\n          -  In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is\n             acceptable.\n\n          -  Patient must have normal hematological cell counts.\n\n          -  Patient must have a life expectancy of >/= 3 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "50", 
        "firstreceived_date": "July 16, 2002", 
        "id_info": {
            "nct_id": "NCT00041795", 
            "org_study_id": "082-2001-005"
        }, 
        "intervention": {
            "intervention_name": "leteprinim potassium (Neotrofin)", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berkeley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94704"
                    }, 
                    "name": "Alta Bates Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burbank", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91505"
                    }, 
                    "name": "Providence St. Joseph Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mission Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91345"
                    }, 
                    "name": "Providence Holy Cross Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NYU Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "The Sarah Cannon Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "12059047", 
                "citation": "Grundman M, Farlow M, Peavy G, Kim HT, Capparelli E, Schultz AN, Salmon DP, Ferris SH, Mobs R, Thomas RG, Schafer K, Campbell K, Hake AM, Schoos B, Thal LJ. A phase I study of AIT-082 in healthy elderly volunteers. J Mol Neurosci. 2002 Jun;18(3):283-93."
            }, 
            {
                "PMID": "11358452", 
                "citation": "Di Iorio P, Virgilio A, Giuliani P, Ballerini P, Vianale G, Middlemiss PJ, Rathbone MP, Ciccarelli R. AIT-082 is neuroprotective against kainate-induced neuronal injury in rats. Exp Neurol. 2001 Jun;169(2):392-9."
            }, 
            {
                "PMID": "10845757", 
                "citation": "Rathbone MP, Middlemiss PJ, Gysbers JW, Andrew C, Herman MA, Reed JK, Ciccarelli R, Di Iorio P, Caciagli F. Trophic effects of purines in neurons and glial cells. Prog Neurobiol. 1999 Dec;59(6):663-90. Review."
            }, 
            {
                "PMID": "8584241", 
                "citation": "Middlemiss PJ, Glasky AJ, Rathbone MP, Werstuik E, Hindley S, Gysbers J. AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells. Neurosci Lett. 1995 Oct 20;199(2):131-4."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041795"
        }, 
        "source": "NeoTherapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NeoTherapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2002"
    }, 
    "geocoordinates": {
        "Alta Bates Comprehensive Cancer Center": "37.872 -122.273", 
        "NYU Medical Center": "40.714 -74.006", 
        "Providence Holy Cross Medical Center": "34.688 -120.436", 
        "Providence St. Joseph Medical Center": "34.181 -118.309", 
        "The Sarah Cannon Cancer Center": "36.166 -86.784", 
        "Washington University School of Medicine": "38.627 -90.199"
    }
}